We show that the allergen house dust mite (HDM) or the mucosal adjuvant cholera toxin promotes cell surface expression of c-Kit and its ligand, stem cell factor (SCF), on DCs. This dual upregulation of c-Kit and SCF results in sustained signaling downstream of c-Kit, promoting IL-6 secretion. Intranasal administration of antigen into c-Kit-mutant mice or neutralization of IL-6 in cultures established from the lung-draining lymph nodes of immunized wild-type mice blunted the T H 2 and T H 17 responses. DCs lacking functional c-Kit or those unable to express membrane-bound SCF secreted lower amounts of IL-6 in response to HDM or cholera toxin. DCs expressing nonfunctional c-Kit were unable to induce a robust T H 2 or T H 17 response and elicited diminished allergic airway inflammation when adoptively transferred into mice. Expression of the Notch ligand Jagged-2, which has been associated with T H 2 differentiation, was blunted in DCs from c-Kit-mutant mice. c-Kit upregulation was specifically induced by T H 2-and T H 17-skewing stimuli, as the T H 1-inducing adjuvant, CpG oligodeoxynucleotide, did not promote either c-Kit or Jagged-2 expression. DCs generated from mice expressing a catalytically inactive form of the p110d subunit of phosphatidylinositol-3 (PI3) kinase (p110 D910A ) secreted lower amounts of IL-6 upon stimulation with cholera toxin. Collectively, these results highlight the importance of the c-Kit-PI3 kinase-IL-6 signaling axis in DCs in regulating T cell responses.
DCs are efficient antigen-presenting cells and can prime naive CD4 + T cells toward a T H 1 or T H 2 response or the recently discovered T H 17 response [1] [2] [3] . Considerable progress has been made in the last decade in our understanding of the molecular basis of T helper responses. We and others have identified the transcription factor GATA-3 as the master regulator of T H 2 differentiation [4] [5] [6] [7] . The transcription factors T-bet and ROR-gt are now recognized as crucial regulators of T H 1 and T H 17 differentiation, respectively 8, 9 . Studies have shown that the nature of the antigen, the antigen concentration, the pattern recognition molecules present and the cytokine milieu are some of the key regulators that determine the outcome of an immune response 1 .
Cytokines are crucial in regulating T helper cell differentiation 1 . Previous studies have shown the T H 2-skewing ability of 11) . More recently, IL-6 has been shown to be the quintessential cytokine regulating T H 17 development in both mice and humans 12, 13 . Notably, in certain immunological responses, such as those elicited by allergens in asthma, both T H 2 and T H 17 responses are evident 14 . In these situations, IL-6 would be a central regulator in not only inhibiting the T H 1 response 11 , but also promoting T H 2 and T H 17 responses 10, 12, 13 . However, mechanisms that regulate IL-6 production in DCs have not been elucidated. Additionally, there have been very few studies 15 that have addressed the role of c-Kit expressed by DCs in modulating immune responses.
Our goal was to determine molecular mechanisms by which a complex allergen such as HDM or the mucosal adjuvant cholera toxin promotes IL-6 production in DCs, which, in turn, induce T H 2 and T H 17 responses. Using microarray analysis to identify novel genes regulated by cholera toxin in bone marrow-derived dendritic cells (BMDCs), we identified marked upregulation of IL-6 and c-Kit expression in cholera toxin-treated DCs as compared to that in control DCs. Because cytokine expression is triggered by activation of cell surface receptors, we hypothesized that c-Kit expression and activation in DCs regulate the production of IL-6 and thereby the induction of a T H 2 or T H 17 response subsequent to DC-T cell interaction. To elucidate the role of c-Kit expressed by DCs in regulating IL-6 production, we used c-Kit-mutant mice (WBB6F1 Kit W/W-v ). These mice have a deletion in the transmembrane region of c-Kit and also a missense mutation in the kinase domain [16] [17] [18] . Our in vitro data with cholera toxin-and HDM-stimulated BMDCs and lung DCs and our in vivo data with two models of allergic airways disease in mice, as well as an adoptive transfer experiment with wildtype (WT) and c-Kit-defective DCs, show that functional c-Kit signaling in DCs via upregulation of c-Kit and membrane-bound SCF is essential for the induction of T H 2 and T H 17 responses. Of note, c-Kit expression was also found to influence expression of the Notch ligand Jagged-2, which has been associated with T H 2 responses 19 . Using p110d-mutant mice with defective PI3 kinase signaling, which constitutes a major signaling pathway downstream of c-Kit, we show that the c-Kit-PI3 kinase signaling axis positively regulates production of IL-6. Thus, we have identified a previously undescribed signaling axis in DCs that promotes the induction of T H 2 and T H 17 responses while markedly inhibiting the T H 1 arm of the immune response.
RESULTS

DC cytokine balance and induction of T H 2 and T H 17 responses
The mucosal adjuvant cholera toxin has been associated with IL-6 production 20 . Recent studies have implicated IL-6 in IL-17 production 12, 13, 21 , which is also involved in allergic airway inflammation 14 . To dissect the importance of cytokines secreted by DCs in influencing T cell response, we analyzed cytokine abundance in culture supernatants of BMDCs stimulated with cholera toxin or the allergen HDM, which causes asthma in humans 22 . Both cholera toxin and HDM promoted IL-6 production from BMDCs (Fig. 1a) . The secretion of the T H 1-skewing cytokine IL-12 p70 was not significantly different between HDM-or cholera toxin-treated DCs and control DCs. A similar cytokine profile of high IL-6 and low IL-12 production by lung DCs was associated with inhibition of T H 1 and promotion of T H 2 response 11 . Neutralization of IL-6 in cocultures of BMDCs and T cells resulted in a cytokine profile that showed a switch in the T helper response to a dominant T H 1 response, with elevated levels of interferon-g (IFN-g) coupled with inhibition of IL-13 and IL-17 production (Fig. 1b) . Furthermore, addition of IL-12 to cholera toxin-stimulated BMDCs switched the response of the T cells in coculture to a T H 1 response by promoting IFN-g production (data not shown). These results show that altering the cytokine balance by neutralizing IL-6 or adding IL-12 diverts the dominant T H 2-and T H 17-skewing property of cholera toxin to a more T H 1 response. We next investigated the role of IL-6 in shaping the immune outcome in vivo in response to the natural allergen HDM. Mice were immunized intranasally with the allergen and the lung-draining lymph nodes were harvested. This protocol of immunization has been shown to prime the T cells from the lung-draining lymph toward a T H 2 response 23 . Immunization with the allergen increased the T H 2 and T H 17 response, whereas neutralization of IL-6 crippled the dominant T H 2 and T H 17 immune response (Fig. 1c) . Intranasal immunization of Il6 À/À mice with ovalbumin (OVA)-cholera toxin or HDM resulted in significant attenuation of both T H 2 and T H 17 responses ( Supplementary  Fig. 1 online) . These results show that whether T cell responses are triggered by BMDCs or lung DCs, IL-6 has a key role in regulating the responses.
Upregulation of c-Kit in DCs by cholera toxin and HDM To further dissect and identify molecular mechanisms underlying IL-6 upregulation by cholera toxin, we undertook a microarray approach to identify genes differentially regulated in BMDCs upon cholera toxin treatment, as this approach had previously allowed us to identify Chi3l3 (chitinase 3 like 3, also known as Ym1), previously associated with allergic airway inflammation, as a statin-induced gene involved in T H 2 differentiation 24 . The microarray data analysis (details to be published elsewhere) revealed the gene encoding c-Kit to be significantly upregulated along with IL-6 in BMDCs upon cholera toxin treatment (Fig. 2a) . Immunoblotting of total cell lysates revealed greater c-Kit expression in cholera toxin-stimulated BMDCs compared to that in control DCs (Fig. 2b) . As determined by flow cytometry, the frequency of cells expressing c-Kit on the cell surface was increased by cholera toxin treatment (Fig. 2c) , and this increase was dose dependent (data not shown). We also investigated whether c-Kit is induced specifically by cholera toxin, or whether an allergen such as HDM can also do the same. Exposure of BMDCs to HDM increased the frequency of c-Kit-expressing cells comparably (Fig. 2c) . Stimulation of human monocytes with cholera toxin has been shown to suppress IL-12 via a cAMP-dependent pathway 25 . We therefore examined the role of cAMP in c-Kit upregulation by cholera toxin by using the specific cAMP antagonist Rp-cAMPS, which blocks cAMPdependent downstream pathways such as the protein kinase A pathway 26 . Rp-cAMPS caused a significant decrease in the number of c-Kit-expressing cells among both cholera toxin-and HDMstimulated DCs in a dose-dependent fashion, with a concomitant decrease in IL-6 production (Fig. 2c) . It is presently unclear how HDM triggers cAMP-protein kinase A-dependent mechanisms in DCs. c-Kit expression on DCs derived from Il6 À/À mice was comparable to that on cells derived from WT mice, suggesting that IL-6 is a downstream target of c-Kit (Fig. 2d) .
c-Kit expression in DCs regulates T H 1 and T H 2 responses
To further understand the functional implications of c-Kit upregulation on DCs, we sorted c-Kit + and c-Kit -cells after stimulation with cholera toxin. The sorted populations were then cultured with T cells from naive DO11.10 mice in the presence of OVA peptide. The supernatants from the coculture were assayed for IL-13, IL-17 and IFN-g abundance by ELISA. The cholera toxin-stimulated BMDCs that were c-Kit + skewed the T cells toward production of high amounts of IL-13 and IL-17 and low amounts of IFN-g (Fig. 3a) . The cytokine profile was different in culture supernatants that included the c-Kit -population, showing higher IFN-g and lower IL-17 and IL-13 levels (Fig. 3a) . In contrast to the high frequency of c-Kit + cells generated in response to cholera toxin, the majority of BMDCs stimulated with CpG oligodeoxynucleotide (ODN), a T H 1-skewing adjuvant, were c-Kit -, and this population of DCs strongly promoted a T H 1 response (Fig. 3b) . These results strengthened our notion that the upregulation of c-Kit on DCs elicits a strong T H 2 and T H 17 response while suppressing the T H 1 response.
c-Kit regulates IL-6 and Notch ligand expression in DCs
The ability of c-Kit -cells to trigger a strong T H 1 response (Fig. 3) suggested that a lack of c-Kit upregulation could be a potential mechanism to subvert a T H 2 response. To test this hypothesis, we isolated lung DCs and stimulated them with T H 2-or T H 1-skewing agents and examined the expression of different molecules associated with DC maturation and T helper differentiation. A significant increase in the percentage of c-Kit-expressing DCs was noted upon treatment with cholera toxin or HDM, but not CpG ODN (Fig. 4a) . In contrast, CpG ODN, but not HDM or cholera toxin, promoted expression of CD40, which is associated with increased IL-12 production in DCs and with the T H 1 response 27 (Fig. 4a) . Because we observed that treatment with cholera toxin or HDM upregulates c-Kit expression in BMDCs and that expression of this molecule is crucial for IL-6 production, we next investigated whether c-Kit signaling is an important component of IL-6 production in BMDCs and, in turn, in the regulation of T cell responses. BMDCs were cultured from WT or Kit W/W-v mice. There was no difference between WT and Kit W/W-v mice with respect to BMDC purity, yield and expression of major histocompatibility complex (MHC) class II and the costimulatory molecules CD40 and CD86 ( Supplementary  Fig. 2 online) . The DCs were incubated with or without cholera toxin or HDM, and the cytokine profile was analyzed by ELISA. DCs from Kit W/W-v mice secreted significantly lower amounts of IL-6 upon cholera toxin or HDM stimulation, indicating that c-Kit signaling in BMDCs is crucial for IL-6 production in response to these agents (Fig. 4b) . The amount of IL-12 p70 in the culture supernatants was not significantly different between the mouse groups; however, treatment with CpG ODN upregulated the production of this cytokine (Fig. 4b) . We observed essentially similar results in DCs isolated from the spleens or the lungs of Kit W/W-v mice (Fig. 4b) , clearly showing that mutations that impair c-Kit signaling affect IL-6 secretion from BMDCs as well as from tissue DCs.
Antigen-presenting cells have been shown to upregulate the Notch ligands Delta-4 and Jagged-2 in response to T H 1-and T H 2-inducing stimuli, respectively 19 . We therefore investigated whether the expression pattern of these ligands was altered in DCs from WT mice compared to Kit W/W-v mice. At the basal level, BMDCs from Kit W/W-v mice had markedly lower Jagged-2 expression compared to DCs from WT mice, suggesting a developmental link between c-Kit and Jagged-2 (Fig. 4c) . Also, cholera toxin treatment stimulated Jagged-2 expression in BMDCs from WT mice (Fig. 4c) . The expression of Delta-4, on the other hand, was not compromised by c-Kit defect and was slightly elevated upon CpG ODN treatment (Fig. 4c) .
To confirm that impaired c-Kit signaling has physiological relevance in T cell responses, we used an in vivo model of airway inflammation in which OVA, in combination with cholera toxin, was administered via the intranasal route 28 to WT and Kit W/W-v mice. After 4 d of rest, the mice were killed and the lung-draining lymph nodes were harvested. The lymph node cells from the Kit W/W-v mice showed fewer IL-13 and IL-17 spot-forming units (SFU) and a slight increase in the number of IFN-g SFU, as determined by enzyme-linked immunosorbent spot (ELISPOT) assay (Fig. 4d) . In a recall response to antigen, lower expression of the T H 2-specific factor GATA-3 (refs. 4,5) was detected in nuclear extracts derived from Kit W/W-v mice, whereas expression of the T H 1-specific factor T-bet was unchanged 9 (Fig. 4e) . Correspondingly, decreased IL-13 abundance was noted in cultures containing lymph node cells from Kit W/W-v mice as compared to those containing cells from WT mice, and the converse was noted for IFN-g abundance (Fig. 4e) . The increase in IFN-g abundance with cells from the Kit W/W-v mice suggested that there would be a decrease in IL-17 production due to its known cross-regulation by IFN-g, which we confirmed by ELISA (Fig. 4e) . As expected, cultures established from lymph nodes of Kit W/W-v mice generated less IL-6 than those established from lymph nodes of WT mice ( Supplementary Fig. 3 online) .
The combination of OVA and CpG ODN elicited a potent T H 1 response (Fig. 4f) that did not differ between the WT and Kit W/W-v mice (Fig. 4g) .Taken together, these data show that c-Kit signaling is essential for the elicitation of a T H 2 response, but not a T H 1 response.
Poor T H 2 response elicitation by Kit W/W-v DCs in vivo Given that Kit W/W-v mice also have a defect in mast cells, which are associated with allergic responses, we tested whether c-Kit deficiency in DCs explained the reduced T H 2 and T H 17 priming in Kit W/W-v mice. To address this, we adoptively transferred either WT or Kit W/W-v DCs into WT recipients with a complete repertoire of all cell types, including mast cells, and examined development of allergic airway inflammation (Fig. 5a) . BMDCs generated from Kit W/W-v mice produced less IL-6 compared to those from WT mice after incubation with OVA and cholera toxin (Fig. 5b) , although both types migrated similarly to lung-draining lymph nodes after intratracheal transfer, as confirmed by visualization of carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled DCs (Fig. 5c) . In mice subjected to repeated antigen challenge after DC transfer, assessment of lung histology (Fig. 5d) , differential cell counts in bronchoaleveolar lavage (BAL) fluid (Fig. 5e) , antigen-specific IgE abundance (Fig. 5f ) and cytokine production (Fig. 5g) showed that BMDCs from Kit W/W-v mice induce less allergic airway inflammation compared to those from WT mice.
We also addressed the role of c-Kit in a different model associated with a T H 17 response, the Klebsiella pneumoniae model of lung infection 29 . WT and Kit W/W-v mice were infected with the bacteria, and the mice were killed on day 4 after the infection (Supplementary Methods online). Analysis of bacterial counts in the mice showed that the c-Kit mutants had significantly fewer colony-forming units in the spleen, liver and lungs ( Supplementary Fig. 4 online) . Notably, the c-Kit mutants also had a higher IFN-g response in the lung-draining lymph nodes, as assayed by ELISPOT technique ( Supplementary  Fig. 4 ). This was similar to the increased IFN-g secretion observed upon neutralization of IL-6 ( Fig. 1) and in response to OVA-cholera toxin in c-Kit mutant mice (Fig. 4d) . Thus, in the Klebsiella infection model, too, compromised c-Kit signaling in the c-Kit mutant mice impairs the T H 17 response and increases the IFN-g response, and the mice show less bacterial burden in several organs.
Allergen-induced membrane-bound stem cell factor in BMDCs We next asked how c-Kit is stimulated to induce IL-6 production in DCs. Previous studies have shown that c-Kit is internalized upon binding its ligand, stem cell factor (SCF, encoded by Kitl), indicating a key role for SCF in regulating the cell surface expression of c-Kit 30 . Analysis of SCF abundance in culture supernatants of control versus cholera toxin-stimulated BMDCs showed lower amounts in the latter cells (Fig. 6a) , and the expression of c-Kit was reduced upon treatment with soluble SCF (Fig. 6b) .
Because SCF is also expressed in a membrane-bound form owing to alternative splicing 31 , we analyzed the expression of membrane-bound SCF by different techniques. The results of immunostaining showed that cholera toxin treatment of BMDCs promoted expression of membrane-bound SCF, rather than the soluble form that is favored in control cells (Fig. 6c) . Cholera toxin or HDM stimulation induced a greater frequency of SCF-expressing BMDCs than did stimulation by CpG ODN, as analyzed by flow cytometry (Fig. 6d) . To further elucidate the functional significance of this differential expression, we used DCs from Kitl sl/sl-d mice, in which expression of the membrane-bound form of SCF is selectively compromised 31, 32 . IL-6 expression was significantly compromised after cholera toxin or HDM stimulation of DCs generated from Kitl sl/sl-d mice (Fig. 6e) . DCs generated from Kitl sl/sl-d mice showed negligible cell surface staining for SCF ( Supplementary Fig. 5 online) .
Among the signaling pathways induced by c-Kit, that of PI3 kinase has a crucial role 33 . The sustained expression of c-Kit after 24 coupled with the high expression of membrane-bound SCF, suggested persistent signaling through c-Kit via PI3 kinase in the DCs. Phosphorylated Akt (phospho-Akt), triggered by activated PI3 kinase 34 , was readily detectable in cell extracts prepared from cholera toxinstimulated BMDCs derived from WT but not Kit W/W-v mice (Fig. 6f) . We next investigated whether cholera toxin-stimulated IL-6 production was compromised in PI3 kinase 110d-mutant mice (p110d D910A/D910A mice). These mice lack the 110d subunit of PI3 kinase and have impaired B and T cell signaling and mounting of allergic airways disease 35, 36 . Cholera toxin-stimulated BMDCs from p110d D910A/D910A mice secreted less IL-6 as compared to cells from WT mice, indicating the involvement of the PI3 kinase pathway in IL-6 production (Fig. 6g) . Thus, c-Kit expressed by BMDCs in conjunction with membrane-bound SCF causes prolonged activation of the PI3 kinase-Akt pathway in DCs that promotes a higher IL-6 and lower IL-12 expression profile in DCs, which, in turn, promotes T cell differentiation toward the T H 2 and T H 17 lineage.
DISCUSSION
The discovery of DCs has enhanced our knowledge of the divergent pathways of the T H 1 and T H 2 responses, as well as the recently discovered T H 17 response. In this study, we show that dual upregulation of c-Kit and membrane-bound SCF on DCs, causing sustained activation of the c-Kit-PI3 kinase signaling axis, is crucial for promoting IL-6 production. Defective c-Kit signaling, associated with reduced IL-6 production, compromises the ability of DCs to mount a robust T H 2 and T H 17 response and allergic airway inflammation in mice.
Our results show that exposure of DCs to selective agents such as the mucosal adjuvant cholera toxin or the allergen HDM, both associated with allergic immune responses 1, 22, 28 , induces expression of both c-Kit and its ligand SCF in the DCs stimulating IL-6 production, which promotes both T H 2 and T H 17 responses. However, upregulation of c-Kit and its ligand was not simply a result of DC maturation, as the T H 1 (IFN-g)-inducing adjuvant CpG ODN did not elicit the same responses. IL-12 production in DCs by microbial stimuli has been tightly linked to CD40 ligation 27 , and IL-12 promotes T H 1 differentiation. Although IL-6 production by DCs has been associated with T H 2 and T H 17 differentiation 10, 11, 20 , no cell surface event in DCs has heretofore been identified that promotes IL-6 and limits IL-12 production. Of note, in mice lacking Rab guanine nucleotide exchange factor-1 (RABGEF1), which is a negative regulator of c-Kit, the abundance of IL-6 was found to be elevated 37 . Collectively, our data show that the activation of the c-Kit-PI3 kinase axis in DCs, stimulating IL-6 production, is a key regulatory mechanism that promotes T H 2 and T H 17 responses and limits the T H 1 response.
Not only did this study unravel a link between c-Kit and IL-6 production in DCs, but also the expression of a Notch ligand, Jagged-2, which is specifically aligned with T H 2 response 19 , was found to be dependent on functional c-Kit. Essential regulatory roles for Notch have been recently identified in the immune system. For example, Notch has been implicated in T cell polarization, which has been associated with upregulation of specific Notch ligands in response to T H 2 or T H 1 stimuli on antigen-presenting cells 19 . We have recently demonstrated cross-talk between Notch-and transforming growth factor-b-induced pathways in antigen-induced tolerance in the airways 38 . Here, we show that DCs expressing functionally inactive c-Kit express low amounts of Jagged-2 compared to DCs from WT mice, thus identifying a potentially crucial role for c-Kit in the expression of a specific Notch ligand during development. The relationship between Jagged-2 and c-Kit is also in line with previous observations showing that the Notch-Jagged-2 axis promotes IL-6 secretion in different cell types 39 . Although Notch activation in CD4 + T cells is important for T H 2 differentiation 19, 40, 41 , bidirectional Notch-Notch ligand signaling has been documented in T helper cell-DC conjugates, with evidence of nuclear translocation of Hes1 and STAT3 in both cell types, Hes1 being a Notch-induced transcription factor which, in turn, promotes STAT3 activation 42 . Thus, the Notch pathway may be necessary for promoting Il6 gene expression in DCs, with c-Kit playing an essential regulatory part in Jagged-2 expression. As suggested by our data, the differential SCF expression seen in cholera toxin-or HDM-stimulated DCs could be a mechanism by which prolonged activation of c-Kit and its downstream targets is achieved. It should be noted that soluble SCF can transiently cause Akt phosphorylation, and phosphorylated Akt can no longer be detected 15 min after addition of SCF 37 . Our data showing persistent phospho-Akt expression in cholera toxinstimulated DCs and the results obtained in cells from Kitl sl/sl-d mice reiterate the fact that the absence of membrane-bound SCF markedly reduces signaling via c-Kit, impairing IL-6 production. Thus, dual upregulation of the c-Kit receptor and the membrane-bound form of SCF contributes to increased IL-6 production from allergen-stimulated DCs.
Although c-Kit has been best studied in the context of mast cells, administration of SCF in vivo has been shown to have mast cell-independent effects 43 . c-Kit-expressing DCs have been shown to modulate NK cell function by increasing the cytolytic and IFN-gsecreting ability of NK cells, thereby defining the consequence of this receptor in at least one aspect of DC function 15 . Another noteworthy aspect of this study is that the authors clearly show that DCs are the pharmacological target of Gleevec administration in vivo, indicating that there are mast cell-independent effects of this tyrosine kinase inhibitor. Although mast cells are known to finely tune T cell responses because of their ability to secrete a variety of cytokines, DCs, being professional antigen-presenting cells, have a quintessential role in the orchestration of the adaptive immune response. Our experiment of adoptive transfer of DCs demonstrated that using the intact mast cell c-Kit signaling that is present in the recipients to cripple c-Kit signaling only in adoptively transferred DCs blunts the T H 2 response, which prevents induction of full-blown allergic airway inflammation. Thus, although mast cells can modulate T cell responses, they are unable to supplant DCs in eliciting a strong T H 2 response. On the basis of these results, it seems probable that defective DC functions may be responsible for the reported lower susceptibility of Kit W/W-v mice to allergic airways disease 44 .
The importance of c-Kit signaling via PI3 kinase has also been explored in our study. Notably, p110d D910A/D910A mice have been shown to be resistant to allergic responses, indicating a positive role for PI3 kinase in mediating T H 2 responses 35 . A previous study has shown a negative role for PI3 kinase signaling in IL-12 p70 production from DCs 45 . Our study shows a positive role for this pathway in IL-6 production from DCs, and our data suggest that sustained phosphorylation of Akt in DCs is required for the expression of specific cytokines, such as IL-6, that can influence the outcome of an immune response. Prolonged c-Kit expression coupled with the expression of membrane-bound SCF ensures sustained Akt activation, as is evident from our study and from previous studies, in which soluble SCF was shown to impede signaling via c-Kit 30 , whereas membrane-bound SCF prolonged c-Kit signaling 46 .
The cytokine balance in the microenvironment is a key regulator of the net immune response. Our study highlights the importance of this balance in regulating T cell responses by demonstrating a central role for c-Kit expressed by DCs in the fine-tuning of the IL-6-IL-12 p70 expression profile. Our findings also have ramifications for DC-based vaccines in cancer therapy, where inhibition of c-Kit may promote the efficacy of the vaccine by augmenting a T H 1 response. DO11.10 transgenic mice were originally provided by K. Murphy at Washington University, St. Louis and were bred at the animal facility at the University of Pittsburgh. We housed all mice under pathogen-free conditions and used them between 6 and 12 weeks of age. Within experiments, the mice were age and sex matched. All studies with mice were approved by the Animal Care and Use Committee at the University of Pittsburgh.
METHODS
Cell culture. For cell culture, we used RPMI 1640 (Gibco) supplemented with 10% heat-inactivated FBS (Gemini), 100 U/ml of penicillin and 100 mg/ml of streptomycin sulfate (Gibco, 1 mM sodium pyruvate (Gibco) and 50 mM 2-mercaptoethanol (Sigma). All reagents used had o0.6 U/ml of LPS. For DC cultures, we removed the femur and tibia of mice and flushed out the bone marrow using a 27-gauge needle. We washed the cells and cultured them with 10 ng/ml recombinant murine granulocyte macrophage colony-stimulating factor (Peprotech) at 1 Â 10 6 cells/ml. On the third day, we refed the cells with fresh medium and cytokine. On day 6, we harvested the loosely adherent cells. Prior to harvesting, the flask was gently shaken at 7 Hz/s for 5 min on a MicroMix shaker (DPC Instruments). We then subjected the cells to purification with magnetically labeled beads specific for mouse CD11c (Miltenyi Biotech). The labeled cells were passed through the magnetized column twice, and CD11c expression of the resulting cells was 498%. The contaminating population of CD3 + and CD19 + cells was negligible. The CD11c + cells were considered immature DCs, as ascertained by low expression of CD40, CD86 and MHC class II (data not shown). We plated the immature DCs at 1 Â 10 6 cells/ml in 12-well plates in medium containing 10 ng/ml GM-CSF with or without cholera toxin (List Biologicals Laboratories) or HDM (Greer Laboratories) for 24 h. We used cholera toxin at 1 mg/ml and HDM at 10 mg/ml, both dissolved in PBS, for stimulating the DCs unless specified otherwise. We stripped both the OVA and the HDM preparations of lipopolysaccharide (LPS) with an EndoTrap column (Profos AG). We estimated the residual LPS in the solutions by the Limulus Amebocyte Lysate assay (Cambrex). The concentration of LPS in the cell cultures containing OVA or HDM was less than 0.1 ng/ml. The cholera toxin contained undetectable LPS as purchased. We isolated the lung and spleen DCs as described previously 47 , although the lung DC protocol was slightly modified. We performed a high-volume lavage to isolate alveolar macrophages. After CD11c separation, we sorted the lung cells on a FACS ARIA machine on the basis of the autofluorescence. We sorted the low autofluorescence cells, which we considered to be dendritic cells, from the high autofluorescence cells, the macrophages, and used them in our experiments. For the inhibition of cAMP, we preincubated the BMDCs with the cAMP antagonist Rp-cAMPS, triethylammonium salt (Calbiochem) for 1 h before stimulation of cells. We harvested the cells and used them in various experiments. We obtained the CD4 + T cells from splenocytes as previously described 28 .
Antibodies. We purchased antibodies for either flow cytometry or blocking experiments from BD Pharmingen unless otherwise stated. We used antibody to CD11c (allophycocyanin-labeled; clone HL3), antibody to CD40 (phycoerythrin (PE)-labeled; clone 3/23), antibody to CD86 (PE-labeled; clone GL1), antibody to CD117 (c-Kit; PE-labeled; clone 2B8) and antibody to MHC class II (Southern Biotech; PE-labeled clone NIMR-4), along with the appropriate isotype controls for flow cytometry. We used antibodies to GATA-3, T-bet, Jagged-2, Delta-4, CREB-1 (Santa Cruz Biotechnology), c-Kit, phospho-Akt (on Thr308) and Akt (Cell Signaling Technology) for western blot analysis. We used antibody to SCF from Chemicon for immunofluorescence studies and for detection of SCF by flow cytometry; we carried out indirect staining with antibody to SCF from Abcam together with PE-conjugated goat-antibody to rat IgG (Serotec). Antibody to IL-6 (clone MP5-20F3) and the isotype control were purchased from BD Pharmingen.
Intranasal antigen instillation. We performed intranasal administration of OVA-cholera toxin or OVA-CpG and ex vivo stimulation of single-cell suspensions of cells from lung-draining lymph nodes with OVA as described previously 28, 47 . We performed the experiments with HDM (Greer Laboratories) as described previously 23 with minor modifications. We anesthetized mice with isoflurane before intranasal administration of any antigen. In the experiments involving immunization of mice, 25 ml of the instilled solution contained 10 ng of residual LPS. We carried out intranasal administration of 25 mg of HDM for 7 consecutive d, and we rested the mice for 3 d. We stimulated single-cell suspensions of the lung-draining lymph nodes ex vivo with HDM (10 mg/ml). We prepared nuclear extracts from OVA-or HDM-stimulated cells after 5 d. The CpG ODN 1826 (5-TCCATGACGTTCCTGACGTT-3), which is known to be optimal for stimulation of mouse cells, and the control ODN 1911 (5-TCCAGGACTTTCCTCAGGTT-3) were used at a concentration of 1 mM to stimulate DCs. The control ODN did not influence cytokine production or expression of any molecules in DCs in initial experiments, as previously reported by us, and was not used in all experiments 47 . The LPS concentration in the ODN preparations was low (o0.1 ng/mg DNA). We purchased the oligonucleotides from Oligos Etc.
Adoptive transfer of DCs into mice and induction of allergic airway inflammation. We isolated CD11c + BMDCs from Kit +/+ and Kit W/W-v mice and incubated them overnight with OVA (100 mg/ml) and cholera toxin (1 mg/ml). We harvested the cells, washed them and adoptively transferred 1 Â 10 6 cells intratracheally into C57BL/6 recipients. After transfer, we rested the mice 10 d and then challenged them by exposure to aerosolized 1% OVA for 7 consecutive d with an ultrasonic nebulizer (Omron Healthcare). We killed the mice and examined the lungs for inflammation 24 h after the last aerosol. We performed cell counting in the BAL fluid and lung histology as previously described 6, 28, 48 , and we performed PAS staining according to the manufacturer's instructions (Richard Allan Scientific) 48 . For tracking of the cells in vivo, we labeled them with CFSE dye after stimulation with OVA and cholera toxin. We labeled 10 Â 10 6 BMDCs with CFSE (1 mM, Invitrogen) for 15 min at 37 1C. We stopped the labeling by washing the cells twice with PBS containing 2% FBS. We then counted the cells again and suspended them at a concentration of 1 Â 10 6 BMDCs in 50 ml of PBS.
Flow cytometry. The staining procedures were essentially as described previously 28 . We gated the live cells using propidium iodide staining and collected at least 10,000 events within the live gate with a FACSCalibur flow cytometer. We performed staining for SCF by first adding the unconjugated primary antibody (1 mg) and incubating on ice for 1 h. We washed the tubes and added the secondary antibody (PE-conjugated goat antibody to rat IgG) at the same concentration and incubated for 0.5 h. We analyzed the data with FlowJo software (Tree Star).
Cell extracts and immunoblotting. We prepared nuclear extracts and total cell lysates as stated previously 24, 49 . We prepared total cell lysates from DCs at 24 h after stimulation using 1Â cell lysis buffer (Cell Signaling).
Microarray analysis. We performed the isolation of RNA and microarray analysis essentially as described previously 24 . We isolated RNA from BMDCs incubated with or without cholera toxin (1 mg/ml) for 24 h. We assessed total RNA quality before cRNA target preparation and labeling. We synthesized cRNA from the total RNA samples with the CodeLink Expression Assay Reagent Kit (GE Healthcare). We fragmented the labeled cRNA and hybridized it to CodeLink UniSet Mouse I Bioarrays (GE Healthcare), which identify 10,012 unique mouse genes. We scanned the hybridized bioarrays with the GenePix 4000B Array Scanner (Axon Instruments). The normalized intensities of all slides were then imported into Spotfire to create one file, which included annotations supplied by CodeLink. Only the 'discovery' genes and genes with good-or low-quality flags were selected with the Spotfire query devices. These selected genes were then exported into Excel. Then the data was formatted into the acceptable form for the DOS-based data analysis program Scoregene. Scoregene globally normalized the data by calculating the geometric mean across the controls and experimentals and then log-transformed the data to base 2. t-test P values were also calculated by Scoregene. Genes with t-test P values o0.05 and a fold change of 1.5 (SLR signal log ratio of 0.5849625) were determined to be statistically significant and selected for hierarchical clustering in Spotfire. The clustering method used was UPGMA (unweighted pair-group method average) with a Euclidean distance similarity measurement. Genes were considered to be significantly upregulated or downregulated if the fold change was greater than 1.5 or less than -1.5. We isolated RNA in three independent experiments from control and cholera toxin-treated BMDCs and pooled bone marrows from at least four mice in each experiment.
Immunofluorescence. We cytospun 1 Â 10 5 cells onto slides and fixed them with 95% ethanol and 5% glacial acetic acid. We blocked the slides with 2% goat serum diluted in PBS and incubated them overnight at 4 1C with the primary antibody to SCF. We washed the slides with PBS and incubated them with the secondary antibody tagged with Cy3 for visualization. We mounted the slides with mounting medium Vectashield containing DAPI stain (Vector Laboratories) to identify the nuclei. We ensured the specificity of staining by using control slides in which the incubation with the primary antibody was skipped.
Enzyme-linked immunosorbent assay. We performed ELISAs for IL-12 p70, IL-6, IL-4, IL-13 and IFN-g with kits from R&D Systems per the manufacturer's instructions. We performed ELISA for soluble SCF with a kit from Peprotech. Unless otherwise indicated, we carried out all statistical analyses using mean values of triplicate wells, and the results shown are representative of two to four independent experiments. We measured OVA-specific IgE abundance as previously described 28 . We derived the concentration of IgE from standard curves generated with pooled sera from mice immunized with OVA-alum and repeatedly challenged with aerosolized OVA, and we assigned the standard an arbitrary unit of 10,000 U/ml.
Enzyme-linked immunosorbent spot. We performed the IL-13, IL-17 and IFN-g ELISPOT assays with kits from eBioscience per the manufacturer's specifications. Briefly, we precoated ELISPOT plates (Millipore 96-well MultiScreen HTS) with the primary antibody at 4 1C overnight. We plated lymph node cells at a concentration of 1 Â 10 5 or 1 Â 10 4 per well and stimulated them with PMA (25 ng/ml) and ionomycin (500 ng/ml) for 24 h. We used biotin-conjugated secondary antibody to detect the secreted cytokine. We developed the plates with Avidin-horseradish peroxidase and peroxidase substrate (Vectastatin). We quantified the SFU with an automated ELISPOT plate reader (ImmunoSpot; Cellular Technology).
Statistical analyses. We used Student's unpaired two-tailed t-test for all statistical analyses. Differences between groups were considered significant when P o 0.05. All statistical analyses (except those performed for microarray data) were performed with GraphPad Prism software.
Accession codes. Gene Expression Omnibus microarray accession code, GSE10815.
Note: Supplementary information is available on the Nature Medicine website.
